Last update 06/2024

			Novelty				Development Stage								
AMR Accelerator Project	**Asset Owner**	**Programme**	**New Class**	**New MoA**	**Mode of Action (MoA)**	**Description**	**Discovery**	**(Pre)-Hit to Lead**	**Lead to Candidate**	**Candidate to Phase I**	**Phase I**	**Phase 2a - alone or in combi-nation**	**Phase 2b - Dose ranging**	**Phase 2b - Regimen selection**	**Phase 2c - Duration rando-mization**
GNA NOW €21 m	NOSOPHARM	NOSO-502	✓	✓	Inhibition bacterial ribosome	NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins, inhibiting the bacterial ribosome with a new mechanism of action.			▶						
TRIC-TB €8 m	BioVersys and GSK	Alpibectir	✓	✓	Transcriptional modulator	Boosting Ethionamide efficacy and lowering the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections and define a new place for Ethionamide in 1st-line tuberculosis treatments.						▶*			
AB-Direct €4 m	GSK	Gepotidacin tissue distribution	✓	✓	Topoisomerase type II inhibitor	Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.					▶				
ERA4TB €208 m		ERA4TB-01	✓	✓	Cholesterol catabolism of mycobacteria	Molecule targeting cholesterol catabolism of mycobacteria.					▶				
		ERA4TB-02	✓	✓	*Mycobacterium tuberculosis* tryptophan synthase	Compound targeting *Mycobacterium tuberculosis* tryptophan synthase, enzyme that catalyses the final two steps in the biosynthesis of tryptophan.			▶						
		ERA4TB-03			Energy metabolism	Compounds targeting energy metabolism (electron chain transport).					▶				
		ERA4TB-04	✓	✓	Lysine transfer RNA synthase	Compound targeting lysine transfer RNA synthase (Rv3598c), which is an essential gene as assessed by transposon mutagenesis.			▶						
		ERA4TB-06	✓	✓	Mmpl3	Mycobacterial membrane protein Large 3 (Mmpl3) compounds with potent in vitro inhibitory and bactericidal activity against *Mycobacterium tuberculosis*.			▶						
		ERA4TB-09	✓	✓	Not known	Natural product analogs active against *Mycobacterium tuberculosis*.			▶						
		ERA4TB-10	✓	✓	DprE1	Piperazinobenzothiazinone derivative as anti-mycobacterial compound that targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1).					▶				
		ERA4TB-11	✓	✓	LeuRS	Small molecule oxaborole inhibitor of Mtb leucyl tRNA synthetase					Phase II of clinical development, Phase I in ERA4TB	▶			
		ERA4TB-13	✓	✓	Cholesterol catabolism of mycobacteria	Targets cholesterol catabolism of *Mycobacterium tuberculosis* (Mtb)				▶					
		ERA4TB-14	✓	✓	Inhibits new target within a known pathway (Mtb energy metabolism) via a novel mode of inhibition	Small molecule compound that inhibits the mycobacterial cytochrome bc1 complex in the cellular respiration pathway, leading to the depletion of ATP, in three mycobacterial species, *M. tuberculosis*, *M. leprae*, and *M. ulcerans*					▶				
		ERA4TB-15	✓	✓	Inhibits new target within a known pathway (Mtb mycolic acid biosynthesis) via a novel mode of inhibition	Novel class of small-molecule antibiotics shown to covalently inhibit the acyl transferase domain of Mtb Pks13, a polyketide synthase involved in the mycolic acid biosynthetic pathway			▶						
		ERA4TB-16	✓	✓	Inhibits new target within a known pathway (Mtb mycolic acid biosynthesis) via a novel mode of inhibition	Novel class of small-molecule antibiotics shown to covalently inhibit the acyl transferase domain of Mtb Pks13, a polyketide synthase involved in the mycolic acid biosynthetic pathway			▶						
		ERA4TB-17	✓	✓	Inhibits a new target within a known pathway (Mtb mycolic acid biosynthesis)	Novel class of small-molecule antibiotics that inhibits FadD32, a key enzyme at the interface between the fatty acid synthase and polyketide synthase biosynthetic pathways and involved in the synthesis of mycolic acid			▶						
		ERA4TB-18	✓	✓	H3D-012895 inhibits a new target within a known pathway (Mtb mycolic acid biosynthesis)	Novel class of small-molecule antibiotics that inhibits FadD32, a key enzyme at the interface between the fatty acid synthase and polyketide synthase biosynthetic pathways and involved in the synthesis of mycolic acid			▶						
RespiriTB €9 m	JANSSEN	BC1 back up	✓	✓	BC1	Lead optimization program on BC1 inhibitors			▶						
		MenG	✓	✓	MenG	H2L medChem for novel menG inhibitors		▶							
		BDQ LAI	✓		ATPase	Novel long acting injectable formulation of bedaquiline for Tb preventive therapy				▶					
		PASA	✓		DHFR	Novel PAS analogues		▶							
		HDT	✓	✓	Various	Exploring of known host directed therapies for TB treatment	▶								
		Mtr	✓	✓	Mtr	Mtr target exploration.	▶								
RespiriNTM €8 m	TBA				not known	Progress novel assets (one FIH start) for Non-Tubercular Mycobacterium (NTM) that may act synergistically with Bedaquiline and cytochrome bc Drugs.		▶							
UNITE4TB €185 m	GSK	GSK656	✓	✓	LeuRS	A first-in-class investigational antitubercular agent which is being developed for the treatment of tuberculosis as part of a future combination regimen. New MoA/not regulatory approved product with this MoA. Suppresses protein synthesis in *Mycobacterium tuberculosis* (Mtb) by inhibiting the enzyme leucyl t-RNA synthetase (LeuRS).								▶	
	Leibniz-HKI/ LMU	BTZ-043	✓	✓	Cell wall synthesis	A first-in-class investigational antitubercular agent which is being developed for the treatment of tuberculosis as part of a future combination regimen. New MoA/not regulatory approved product with this MoA. BTZ-043 inhibits an enzyme (BTZ-043) with is essential for cell wall synthesis in *Mycobacterium tuberculosis.*							▶	▶	

Accelerating scientific discoveries in the antimicrobial resistance (AMR) field

COMBINE €25 m	Providing learnings derived from shared vaccine and/or antibacterial clinical trial data, and improving understanding of variability and translatability of animal models of bacterial infection.
PrIMAVeRa €9 m	Developing a decision-making tool accessing health and economic outcomes of vaccines on the reduction of AMR.

*This Phase 2a proof of concept trial is funded by the European & Developing Countries Clinical Trials Partnership and supported by the European Union.